BridgeBio Pharma, Inc. (BBIO) Key Metrics
BBIO valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $12.98B
- Enterprise value
- $14.62B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 18.2 10-yr median 32.3
- Price / book
- 123.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.97
BBIO key metrics, 2017–2025
Fiscal year ended December 31, 2025 · U.S. dollarsBBIO valuation Price multiples at each fiscal year-end price.
Price / sales+30.6%
30.0
2025 · hover or tap a bar for each year
20172025
Free cash flow yield+7.3 pts
−3.0%
2025 · hover or tap a bar for each year
20172025
BBIO returns How much profit the business earns on the capital it uses.
Return on assets−5.5 pts
−78.6%
2025 · hover or tap a bar for each year
20172025
Free cash flow margin+146.1 pts
−89.0%
2025 · hover or tap a bar for each year
20172025
Asset turnover+78.7%
0.54
2025 · hover or tap a bar for each year
20172025
BBIO per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+113.5%
$2.55
2025 · hover or tap a bar for each year
20172025
Earnings per share
−$3.70
2025 · hover or tap a bar for each year
20172025
Free cash flow per share
−$2.27
2025 · hover or tap a bar for each year
20172025
Book value per share
−$10.53
2025 · hover or tap a bar for each year
20172025
Shares outstanding+6.0%
197.2M
2025 · hover or tap a bar for each year
20172025
BBIO financial health Debt, liquidity and how easily interest is covered.
Net debt+$1.1B
$2.14B
2025 · hover or tap a bar for each year
20172025
Current ratio−43.9%
2.62
2025 · hover or tap a bar for each year
20172025
Interest coverage
-10.7
2025 · hover or tap a bar for each year
20172025
Debt / assets+54.9%
2.92
2025 · hover or tap a bar for each year
20172025
BBIO efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+47 days
52 days
2025 · hover or tap a bar for each year
20172025
Days of inventory
173 days
2025 · hover or tap a bar for each year
20172025
Days payables outstanding−658 days
296 days
2025 · hover or tap a bar for each year
20172025
Cash conversion cycle+94 days
-71 days
2025 · hover or tap a bar for each year
20172025
Capex / revenue−0.2 pts
0.2%
2025 · hover or tap a bar for each year
20172025
BBIO valuation history
Fiscal year-endToday9-year median
BBIO returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BBIO debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BBIO cash returned to shareholders
DividendsBuybacksFree cash flow
BBIO price vs earnings per share
Share price at year-endEPS (right axis)
BBIO key metrics
2017–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Valuation | |||||||||
| Market capitalization | $15.09B | $5.11B | $6.57B | $1.12B | $2.41B | $8.39B | $3.68B | — | — |
| Enterprise value | $17.23B | $6.16B | $7.88B | $2.38B | $3.30B | $8.28B | $3.23B | — | — |
| Price / sales | 30.0 | 23.0 | 706.4 | 14.5 | 34.5 | — | 90.8 | — | — |
| Price / book | — | — | — | — | — | 144.9 | 9.0 | — | — |
| EV / sales | 34.3 | 27.7 | 846.7 | 30.6 | 47.3 | — | 79.6 | — | — |
| Earnings yield | −4.8% | −10.5% | −9.8% | −42.8% | −23.4% | −5.3% | −7.1% | — | — |
| Free cash flow yield | −3.0% | −10.2% | −8.0% | −37.9% | −22.7% | −4.9% | −7.0% | — | — |
| Dividend yield | — | — | — | — | 0.2% | 6.4% | 0.0% | — | — |
| Shareholder yield (dividends + buybacks) | 0.3% | 0.1% | 0.1% | 0.1% | 8.7% | 7.3% | 0.0% | — | — |
| Share price at fiscal year-end | $76.49 | $27.44 | $40.37 | $7.62 | $16.68 | $71.11 | $35.05 | — | — |
| Per share | |||||||||
| Revenue per share | $2.55 | $1.19 | $0.06 | $0.53 | $0.48 | $0.07 | $0.39 | $0.00 | $0.00 |
| Earnings per share | −$3.70 | −$2.88 | −$3.95 | −$3.26 | −$3.90 | −$3.80 | −$2.48 | −$1.42 | −$0.33 |
| Operating cash flow per share | −$2.26 | −$2.80 | −$3.24 | −$2.84 | −$3.45 | −$3.39 | −$2.41 | −$1.48 | −$0.44 |
| Free cash flow per share | −$2.27 | −$2.80 | −$3.25 | −$2.89 | −$3.78 | −$3.45 | −$2.46 | −$1.68 | −$0.44 |
| Cash per share | $2.98 | $3.66 | $2.67 | $3.20 | $5.80 | $5.15 | $5.20 | $4.72 | $1.00 |
| Book value per share | −$10.53 | −$7.89 | −$8.32 | −$8.51 | −$6.03 | $0.49 | $3.89 | −$1.78 | −$0.63 |
| Tangible book value per share | −$10.67 | −$8.02 | −$8.48 | −$8.70 | −$6.34 | $0.49 | $3.89 | −$1.78 | −$0.63 |
| Dividends per share | — | — | — | — | $0.03 | $4.55 | $0.01 | $0.00 | $0.01 |
| Capex per share | $0.01 | $0.01 | $0.01 | $0.04 | $0.33 | $0.06 | $0.05 | $0.20 | $0.01 |
| Debt per share | $13.83 | $9.30 | $10.69 | $11.69 | $11.96 | $4.20 | $0.87 | $0.59 | $1.56 |
| Shares outstanding | 197.2M | 186.1M | 162.8M | 147.5M | 144.4M | 118.0M | 105.1M | 92.3M | 92.3M |
| Change in shares outstanding | +6.0% | +14.3% | +10.4% | +2.2% | +22.3% | +12.3% | +13.8% | 0.0% | — |
| Returns & profitability | |||||||||
| Return on equity (ROE) | — | — | — | — | — | −192.4% | −213.1% | — | — |
| Return on assets (ROA) | −78.6% | −73.1% | −110.0% | −58.8% | −65.5% | −67.2% | −47.5% | −46.4% | −31.2% |
| Return on tangible assets | −80.3% | −59.8% | −123.7% | −81.0% | −58.1% | −63.8% | −41.2% | −28.1% | −31.2% |
| Free cash flow margin | −89.0% | −235.1% | — | −548.4% | −783.4% | — | −637.9% | — | — |
| Financial health | |||||||||
| Total debt | $2.73B | $1.73B | $1.74B | $1.72B | $1.73B | $495.8M | $91.8M | $54.5M | $143.9M |
| Cash & short-term investments | $587.5M | $681.1M | $434.9M | $471.9M | $836.7M | $607.1M | $546.0M | $436.1M | $92.0M |
| Net debt | $2.14B | $1.05B | $1.30B | $1.25B | $889.5M | −$111.3M | −$454.2M | −$381.6M | $51.9M |
| Debt / equity | — | — | — | — | — | 8.56 | 0.22 | — | — |
| Debt / assets | 2.92 | 1.88 | 3.18 | 2.77 | 1.70 | 0.70 | 0.15 | 0.12 | 1.47 |
| Current ratio | 2.62 | 4.67 | 3.32 | 4.52 | 6.58 | 6.72 | 9.42 | 13.67 | 11.36 |
| Quick ratio | 2.52 | 4.67 | 3.20 | 4.21 | 7.09 | 6.72 | 9.42 | 13.67 | 11.36 |
| Interest coverage | -10.7 | -6.0 | -7.5 | -6.4 | -12.3 | -12.9 | -30.4 | -72.1 | — |
| Working capital | $465.7M | $566.3M | $333.7M | $427.4M | $753.8M | $547.2M | $508.2M | $412.6M | $88.6M |
| Invested capital | $64.7M | −$418.4M | −$49.3M | −$3.0M | $19.1M | −$53.4M | −$45.7M | −$545.6M | −$6.1M |
| Tangible asset value | −$2.10B | −$1.48B | −$1.37B | −$1.27B | −$910.5M | $107.9M | $476.0M | −$101.5M | −$54.7M |
| Net current asset value | −$2.26B | −$1.66B | −$1.41B | −$1.32B | −$989.5M | $47.1M | $412.9M | −$121.2M | −$55.6M |
| Graham net-net per share | −$11.70 | −$9.09 | −$8.87 | −$9.25 | −$7.35 | $0.10 | $3.73 | −$1.41 | −$0.66 |
| Capital allocation | |||||||||
| Dividends paid | — | — | — | — | $3.8M | $537.0M | $997,000 | $0 | $1.2M |
| Share buybacks (net) | $48.3M | $7.5M | $6.9M | $1.6M | $204.7M | $75.7M | $0 | $0 | $0 |
| Capex / revenue | 0.2% | 0.4% | 14.0% | 8.1% | 69.2% | 91.1% | 12.7% | — | — |
| Capex / depreciation | 0.20 | 0.15 | 0.20 | 0.93 | 8.26 | 5.16 | 1.66 | 74.20 | 1.78 |
| Stock-based compensation / revenue | 26.5% | 43.2% | 1,236.3% | 117.9% | 142.7% | 708.7% | 52.7% | — | — |
| R&D / revenue | 95.1% | 228.2% | 4,898.5% | 514.5% | 646.9% | 4,085.9% | 517.6% | — | — |
| SG&A / revenue | 105.8% | 122.8% | 1,618.7% | 184.4% | 275.7% | 1,766.1% | 232.6% | — | — |
| Efficiency | |||||||||
| Days sales outstanding | 52.4 | 5.3 | 369.4 | 86.6 | 103.4 | — | 25.6 | — | — |
| Days of inventory on hand | 172.7 | — | 4,072.5 | -1,645.7 | -8,075.6 | — | — | — | — |
| Days payables outstanding | 295.9 | 954.1 | 1,657.3 | 1,245.8 | 1,220.7 | 1,051.8 | 1,632.4 | — | 2,646.2 |
| Cash conversion cycle (days) | -70.8 | -165.0 | 2,784.6 | -2,805.0 | -9,192.9 | — | -1,606.8 | — | — |
| Receivables turnover | 6.97 | 68.56 | 0.99 | 4.22 | 3.53 | — | 14.26 | — | — |
| Payables turnover | 1.23 | 0.38 | 0.22 | 0.29 | 0.30 | 0.35 | 0.22 | — | 0.14 |
| Inventory turnover | 2.11 | — | 0.09 | — | — | — | — | — | — |
| Asset turnover | 0.54 | 0.30 | 0.02 | 0.09 | 0.08 | 0.01 | 0.07 | 0.00 | 0.00 |
| Average receivables | $72.1M | $3.2M | $9.4M | $18.4M | $19.7M | — | $2.8M | — | — |
| Average payables | $22.9M | $10.1M | $11.1M | $11.7M | $10.4M | $8.9M | $11.2M | $7.7M | $1.9M |
| Average inventory | $13.4M | $8.3M | $27.3M | −$15.5M | −$68.9M | — | — | — | — |
| Intangibles / total assets | 3.0% | 2.6% | 4.8% | 4.6% | 4.4% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from BBIO's annual financial statements (latest annual report filed February 24, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BBIO valuation and financial ratios
It ended the year with $2.7 billion of debt and $587.5 million in cash and short-term investments, net debt of $2.1 billion. It returned $48.3 million to shareholders: $0 in dividends and $48.3 million in share buybacks. The share count rose 113.6% from 92.3M to 197.2M over 8 years.
See the BBIO income statement, the BBIO chart for price history, or the BBIO stock overview for the latest quote and news.
BBIO key metrics FAQ
How much debt does BridgeBio Pharma have?
BridgeBio Pharma had total debt of $2.7 billion at the end of fiscal 2025.
Does BridgeBio Pharma buy back its shares?
Yes. BridgeBio Pharma spent $48.3 million on net share repurchases in fiscal 2025 Shares outstanding changed +6.0% over the year, to 197.2M..
What is BridgeBio Pharma's free cash flow yield?
BridgeBio Pharma generated -$447.0 million of free cash flow in fiscal 2025, a free cash flow yield of −3.0% on its market value at year-end ($15.1 billion).
What is BridgeBio Pharma's current ratio?
BridgeBio Pharma's current ratio was 2.62 at the end of fiscal 2025: current assets were 2.62 times current liabilities.